Navigation Links
CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the Roth Capital Partners 20th Annual OC Growth Stock Conference, February 19, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, Calif.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30 a.m., Pacific Time.

CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valves, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Financial Officer Fleishman Hillard

and Chief Operating Officer Phone: 770-419-3355

Phone: 404-739-0150


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
2. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
3. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
4. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
5. CryoLife Announces Record Preservation Services and Product Revenues for 2007
6. CryoLife to Present at OneMedPlace Finance Forum
7. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
8. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
9. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
10. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
11. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at ... years. What sets them apart from other cuvette manufacturers is their supercharged customer ... website. On top of this steady flow of inside information, they have recently ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare Conference ... , Wednesday, February 10, 2016 Time:  , 11:55am ... . --> An audio webcast of this ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
Breaking Biology News(10 mins):